Fig. 3.
Fig. 3. Biodistributions of radioactivity in blood, tumor, kidney, liver, and lung. / Ramos xenograft-bearing athymic mice were injected with either pretargeted BC8-SA conjugate (A) or pretargeted 1F5-SA conjugate (B). Mice were injected with 1.4 nmol unlabeled BC8-SA or 1.4 nmol unlabeled 1F5-SA, followed 20 hours later by 5.8 nmol clearing agent and 2 hours after that by 1.2 nmol 111In-DOTA-biotin. Groups of 5 mice were killed 24, 48, 96, and 144 hours after injection of each mAb-SA conjugate, and the radioactivity in blood, tumor, and normal organs were quantified by gamma counting and expressed as the percentage of the injected dose of radioactivity present per gram of tissue (% ID/g). Tumor (●), blood (○), kidney (▴), liver (*), lung (⋄).

Biodistributions of radioactivity in blood, tumor, kidney, liver, and lung.

Ramos xenograft-bearing athymic mice were injected with either pretargeted BC8-SA conjugate (A) or pretargeted 1F5-SA conjugate (B). Mice were injected with 1.4 nmol unlabeled BC8-SA or 1.4 nmol unlabeled 1F5-SA, followed 20 hours later by 5.8 nmol clearing agent and 2 hours after that by 1.2 nmol 111In-DOTA-biotin. Groups of 5 mice were killed 24, 48, 96, and 144 hours after injection of each mAb-SA conjugate, and the radioactivity in blood, tumor, and normal organs were quantified by gamma counting and expressed as the percentage of the injected dose of radioactivity present per gram of tissue (% ID/g). Tumor (●), blood (○), kidney (▴), liver (*), lung (⋄).

Close Modal

or Create an Account

Close Modal
Close Modal